comparemela.com

Latest Breaking News On - Monaco asset management - Page 1 : comparemela.com

Monashee Investment Management LLC Reduces Stake in Gossamer Bio, Inc (NASDAQ:GOSS)

Monashee Investment Management LLC lessened its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 34.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,459,854 shares of the company’s stock after selling 1,844,358 shares during the period. Gossamer Bio […]

DG Capital Management LLC Has $3 52 Million Stake in VEON Ltd (NASDAQ:VEON)

DG Capital Management LLC lowered its position in shares of VEON Ltd. (NASDAQ:VEON – Free Report) by 73.5% in the fourth quarter, HoldingsChannel reports. The fund owned 178,580 shares of the Wireless communications provider’s stock after selling 494,692 shares during the period. VEON accounts for approximately 2.2% of DG Capital Management LLC’s investment portfolio, making […]

750,000 Shares in bluebird bio, Inc (NASDAQ:BLUE) Bought by Weiss Asset Management LP

Weiss Asset Management LP acquired a new position in shares of bluebird bio, Inc. (NASDAQ:BLUE – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 750,000 shares of the biotechnology company’s stock, valued at approximately $1,035,000. Weiss Asset Management LP owned approximately 0.69% of […]

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Fifty Day Moving Average of $2 09

Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.09 and traded as low as $1.85. ProQR Therapeutics shares last traded at $1.88, with a volume of 70,200 shares traded. Analysts Set New Price […]

bluebird bio, Inc (NASDAQ:BLUE) Shares Sold by Contrarius Investment Management Ltd

Contrarius Investment Management Ltd lowered its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE – Free Report) by 7.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,206,506 shares of the biotechnology company’s stock after selling 101,496 shares during the period. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.